Metabolic engineering of Chinese hamster ovary cells: Towards a bioengineered heparin
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Heparin is the most widely used pharmaceutical to control blood coagulation in modern medicine. A health crisis that took place in 2008 led to a demand for production of heparin from non-animal sources. Chinese hamster ovary (CHO) cells, commonly used mammalian host cells for production of foreign pharmaceutical proteins in the biopharmaceutical industry, are capable of producing heparan sulfate (HS), a related polysaccharide naturally. Since heparin and HS share the same biosynthetic pathway, we hypothesized that heparin could be produced in CHO cells by metabolic engineering. Based on the expression of endogenous enzymes in the HS / heparin pathways of CHO-S cells, human N-deacetylase/N-sulfotransferase (NDST2) and mouse heparan sulfate 3-O-sulfotransferase 1 (Hs3st1) genes were transfected sequentially into CHO host cells growing in suspension culture. Transfectants were screened using quantitative RT-PCR and Western blotting. Out of 120 clones expressing NDST2 and Hs3st1, 2 clones, Dual-3 and Dual-29, were selected for further analysis. An antithrombin III (ATIII) binding assay using flow cytometry, designed to recognize a key sugar structure characteristic of heparin, indicated that Hs3st1 transfection was capable of increasing ATIII binding. An anti-factor Xa assay, which affords a measure of anticoagulant activity, showed a significant increase in activity in the dual-expressing cell lines. Disaccharide analysis of the engineered HS showed a substantial increase in N-sulfo groups, but did not show a pattern consistent with pharmacological heparin, suggesting that further balancing the expression of transgenes with the expression levels of endogenous enzymes involved in HS / heparin biosynthesis might be necessary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heparan sulphate proteoglycans fine-tune mammalian physiology
Bishop, J. R., Schuksz, M., & Esko, J. D. (2007) · Nature · doi:10.1038/nature05817 · Cited by 1,631
Self-citationOrder Out of Chaos: Assembly of Ligand Binding Sites in Heparan Sulfate
Esko, J. D., & Selleck, S. B. (2002) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.71.110601.135458 · Cited by 1,495 · cited 3×
“The mechanism that controls the HS/heparin biosynthetic pathway is also still unclear, but one widely supported hypothesis is that NDST is involved in the termination of sulfonation in HS/heparin (Esko and Selleck, 2002).”
BackgroundInfluentialSelf-citationCapila, I., & Linhardt, R. J. (2002) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20020201)41:3<390::aid-anie390>3.0.co;2-b · cited 1×
“HS has considerably lower anticoagulant activity than heparin (Marcum and Rosenberg, 1987), but both are mediated through the interaction of a unique pentasaccharide motif (an antithrombin (ATIII) binding site), with ATIII, a serine-protease inhibitor (Capila and Linhardt, 2002; Muszbek et al., 2010).”
BackgroundSelf-citation
Cited by
Advances in Mammalian cell line development technologies for recombinant protein production
Lai, T., Yang, Y., & Ng, S. (2013) · Pharmaceuticals · doi:10.3390/ph6050579 · Cited by 322
“Taking it further, there has been an attempt to produce non protein therapeutic like heparin in CHO cells [135].”
BackgroundHeparin: Past, Present, and Future
Oduah, E., Linhardt, R., & Sharfstein, S. (2016) · Pharmaceuticals · doi:10.3390/ph9030038 · Cited by 281
Self-citationCHO cell engineering to prevent polypeptide aggregation and improve therapeutic protein secretion
Le Fourn, V., Girod, P.-A., Buceta, M., Regamey, A., & Mermod, N. (2014) · Metabolic Engineering · doi:10.1016/j.ymben.2012.12.003 · Cited by 144
Druz, A., Son, Y., Betenbaugh, M., & Shiloach, J. (2013) · Metabolic Engineering · doi:10.1016/j.ymben.2012.12.004 · Cited by 73
“Chinese hamster ovary (CHO) cells are the most commonly used mammalian culture system for production of biologicals due to their ability to make recombinant proteins with humanlike post-translational modifications (Baik et al. 2012; Barron et al. 2011b; Kramer et al. 2010; Muller et al. 2008).”
BackgroundGlycoengineering in CHO cells: advances in systems biology
Tejwani, V., Andersen, M. R., Nam, J. H., & Sharfstein, S. T. (2018) · Biotechnology Journal · doi:10.1002/biot.201700234 · Cited by 70
Self-citation
Metadata
- Authors
- Baik, J. Y., Gasimli, L., Yang, B., Datta, P., Zhang, F., Glass, C. A., Esko, J. D., Linhardt, R. J., & Sharfstein, S. T.
- Venue
- Metabolic Engineering
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 14
- Issue
- 2
- Pages
- 81-90
- ISSN
- 1096-7176 (ISSN-L)
- OpenAlex
- W2097399693
- Cited by
- 73
- References
- 3
- FWCI
- 3.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolic engineering of Chinese hamster ovary cells: Towards a bioengineered heparin. https://app.cochat.ai/papers/10.1016/j.ymben.2012.01.008
- The paper
- Baik, J. Y., Gasimli, L., Yang, B., Datta, P., Zhang, F., Glass, C. A., Esko, J. D., Linhardt, R. J., & Sharfstein, S. T. (2012). Metabolic engineering of Chinese hamster ovary cells: Towards a bioengineered heparin. Metabolic Engineering. https://doi.org/10.1016/j.ymben.2012.01.008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.